Inclusion Criteria:  18-65 years of age (SZ); 18-75 years of age (CON) Women and men All races and ethnicities Psychiatric diagnoses:  Patient participants (SZ): Meet DSM-5 criteria for schizophrenia or schizoaffective disorder Healthy control participants (CON): No personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st-or 2nd- degree relatives  Able to read, speak, and understand English Able and willing to provide written informed consent; and willing to commit to the study protocol, including 2-year longitudinal follow-up  Exclusion Criteria:  • Compromised cognitive function: Both SZ and CON participants: Estimated premorbid intellectual ability <75 age-corrected score on Wide Range Achievement Test-4/Word Reading Subtest (WRAT-4) CON participants: <26 score on the Montreal Cognitive Assessment (MoCA)  Neurological or medical disorder that may affect brain function (history of stroke, head injury with a loss of consciousness >10 min, seizure disorder, AIDS, poorly controlled hypertension, poorly controlled diabetes, decompensated lung disease, etc.) Co-morbid DSM-5 diagnosis of drug/alcohol use disorder in prior 3 months Current treatment with benzodiazepine or non-benzodiazepine sedatives/hypnotics, and/or anticonvulsants Presence of ferromagnetic objects in body Weight or body size exceeding MRI scanner capacity [>300 lbs] Claustrophobia in MRI scanner Pregnant women Breastfeeding women (VASO scan will not be administered. All other imaging modalities are safe to administer.) Impaired kidney function: Glomerular Filtration Rate (GFR) < 30 ml/min/1.73m2 (VASO scan will not be administered due to an association between Gadolinium-based MR contrast use and Nephrogenic Systemic Fibrosis in individuals with severely impaired renal function. All other imaging modalities are safe to administer.) History of hypersensitivity to any MRI contrast agent (VASO scan will not be administered. All other imaging modalities are safe to administer.)